



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Giulia Bon
giulia.bon@ifo.it

SPECIALTY SECTION
This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 07 October 2022
ACCEPTED 21 October 2022
PUBLISHED 31 October 2022

CITATION
Loria R, Vici P, Di Lisa FS, Soddu S,
Maugeri-Saccà M and Bon G (2022)
Corrigendum: Cross-resistance
among sequential cancer therapeutics:
An emerging issue.
Front. Oncol. 12:1063651.
doi: 10.3389/fonc.2022.1063651

COPYRIGHT
© 2022 Loria, Vici, Di Lisa, Soddu,
Maugeri-Saccà and Bon. This is an
open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Corrigendum: Cross-resistance among sequential cancer therapeutics: An emerging issue

Rossella Loria¹, Patrizia Vici², Francesca Sofia Di Lisa^{2,3},
Silvia Soddu¹, Marcello Maugeri-Saccà⁴ and Giulia Bon^{1*}

¹Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy, ²Unit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, Rome, Italy, ³Medical Oncology A, Department of Radiological, Oncological, and Anatomico-Pathological Sciences, Umberto I University Hospital, University Sapienza, Rome, Italy, ⁴Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy

KEYWORDS

targeted-therapy, cancer therapeutics resistance, cross-resistance, sequential therapeutics, personalized oncology

A Corrigendum on

Cross-resistance among sequential cancer therapeutics: An emerging issue

By Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-Saccà M, Bon G. (2022) *Front. Oncol.* 12:877380. doi: 10.3389/fonc.2022.877380

In the published article, there was an error in affiliations 1, 2, and 4. In these affiliations, “Istituto di Ricerca e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome, Italy” has been changed to “IRCCS Regina Elena National Cancer Institute, Rome, Italy”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.